Article: Surgical strategy for medication-related osteonecrosis of the jaw (MRONJ) on maxilla: A multicenter retrospective study

Background/purpose: Because the anatomy and the nature of the bone tissue between the mandible and maxilla are largely different, more site-specific studies are required to improve the healing rate on medication-related osteonecrosis of the jaw (MRONJ). The present study assessed maxillary MRONJ that was treated by surgery to understand its clinical characteristics, and to identify critical factors that influenced outcomes.

Materials And Methods: The medical records of 54 patients with maxillary MRONJ who underwent surgery were retrospectively reviewed. Variables related to the prognosis of MRONJ were extracted from the medical records and imaging, and were statistically analyzed. We also evaluated the concomitant maxillary sinusitis (MS) after the surgical treatment of MRONJ, based on CT evaluation and change of symptoms.

Results: The healing rate of surgery for maxillary MRONJ was 85.2%, which suggested that surgical treatment is an effective strategy for treating maxillary MRONJ. Multivariate analysis revealed that postoperative residual necrotic bone was a poor prognosticator for maxillary MRONJ. Among 10 patients who did not obtain healing of MS postoperatively, 8 patients showed an improvement.

Conclusion: Our results indicate that surgical treatment is an appropriate strategy for maxillary MRONJ and complete resection of necrotic bone (i.e., extensive surgery) is needed to obtain complete healing of maxillary MRONJ. Concomitant MS tends to be healed or improved clinically in combination with the healing of maxillary MRONJ.

Citing Articles

Ruan H, Li M, Zhang Z, Ma H, He Y Clin Oral Investig. 2024; 28(10):549.

PMID: 39317736 PMC: 11422288. DOI: 10.1007/s00784-024-05911-z.

Application of bone perforation in the surgery of medication-related osteonecrosis of the jaw in stage Ⅱ.

Gao N, Tian M, Sun Y, Wang D, Sun G Hua Xi Kou Qiang Yi Xue Za Zhi. 2024; 42(5):629-635.

PMID: 39304506 PMC: 11493859. DOI: 10.7518/hxkq.2024.2024133.

Resemblances and differences between osteoradionecrosis of the jaw and medication-related osteonecrosis of the jaw.

Golu M, Pascanu I, Petrovan C, Mocan S, Cosarca A, Temistocle D Med Pharm Rep. 2024; 97(1):76-83.

PMID: 38344330 PMC: 10852124. DOI: 10.15386/mpr-2610.

Oral administration of Bifidobacterium breve improves anti-angiogenic drugs-derived oral mucosal wound healing impairment via upregulation of interleukin-10.

Li Q, Li Y, Qiao Q, Zhao N, Yang Y, Wang L Int J Oral Sci. 2023; 15(1):56.

PMID: 38072973 PMC: 10711028. DOI: 10.1038/s41368-023-00263-y.

Risk Factors for Medication-Related Osteonecrosis of the Jaw-A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid.

Ciobanu G, Camen A, Ionescu M, Vlad D, Munteanu C, Gheorghita M J Clin Med. 2023; 12(11).

PMID: 37297941 PMC: 10253558. DOI: 10.3390/jcm12113747.

References

1.

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

2.

Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T . Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis. J Bone Miner Res. 2017; 32(10):2022-2029. DOI: 10.1002/jbmr.3191. View

3.

Voss P, Vargas Soto G, Schmelzeisen R, Izumi K, Stricker A, Bittermann G . Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla. Head Face Med. 2016; 12:3. PMC: 4702393. DOI: 10.1186/s13005-015-0099-0. View

4.

Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S . Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015; 44(5):568-85. DOI: 10.1016/j.ijom.2015.01.026. View

5.

Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P . A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014; 50(11):1049-57. DOI: 10.1016/j.oraloncology.2014.08.016. View

6.

Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C . Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2014; 43(2):290-3. DOI: 10.1016/j.jcms.2014.11.014. View

7.

Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B . Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer. 2009; 18(4):449-60. DOI: 10.1007/s00520-009-0688-1. View

8.

Fleisch H . Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med. 1997; 29(1):55-62. DOI: 10.3109/07853899708998743. View

9.

Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A . Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig. 2018; 22(2):597-615. DOI: 10.1007/s00784-017-2325-6. View

10.

Lopes R, Rabelo G, Rocha A, Carvalho P, Alves F . Surgical Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw: Six-Year Experience of a Single Institution. J Oral Maxillofac Surg. 2015; 73(7):1288-95. DOI: 10.1016/j.joms.2015.01.008. View

11.

Wasserzug O, Kaffe I, Lazarovici T, Weissman T, Yahalom R, Fliss D . Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects. Am J Rhinol Allergy. 2017; 31(1):36-39. DOI: 10.2500/ajra.2017.31.4395. View

Surgical Strategy for Medication-related Osteonecrosis of the Jaw (MRONJ) on Maxilla: A Multicenter Retrospective Study